Indi Molecular Publishes Data on KRas in Analytical Chemistry Demonstrating Allosteric Inhibition and Accelerated Discovery Time of Indi Molecular’s Proprietary PCC Technology

Culver City, CA, August 3, 2018 - Indi Molecular, an emerging biotechnology company, today announced it has published preclinical data in Analytical Chemistry demonstrating the development of a barcoded rapid assay platform for the analysis of hits from PCC macrocyclic peptide library screens.

Read More
Bert Lai
Indi Molecular Raises $11.5M Series A to Accelerate PCC Platform Development

CULVER CITY, CA – June 28, 2017 – Indi Molecular, an emerging life sciences company that is developing a novel, synthetic class of binders with antibody-like properties called protein catalyzed capture agents (PCCs), announced today that it has raised a $11.5 million Series-A financing led by M Ventures (Merck Ventures BV, Amsterdam, the Netherlands, a subsidiary of Merck KGaA, Darmstadt Germany known as M Ventures in the United States and Canada), the strategic corporate venture capital arm of Merck KGaA Darmstadt, Germany; Legend Capital, a venture capital/private equity fund based in Beijing; Sabey Corporation; and existing investors including Asset Management Ventures. As part of the financing, Dr. Andreas Jurgeit from Merck Ventures and Dr. Darren Cai from Legend Capital will join Indi Molecular’s board. The Series-A proceeds will be used to establish a high throughput PCC discovery platform and to advance existing leads in PET immuno-oncology imaging to clinical stage.

Read More
Press ReleaseTori Cox
Landmark Indi Molecular® Publication in Nature Chemistry Suggests PCC Binding Technology May Enable Therapeutics for Previously Undruggable Targets Based on Mutations of A Single Amino Acid

CULVER CITY, CA – (April 13, 2015) – Researchers at Caltech and Indi Molecular announced today a landmark publication in Nature Chemistry suggesting that the PCC (protein catalyzed capture) agent binding technology may enable the creation of highly specific therapeutics for targets that have long been considered undruggable. PCC technology was invented at Caltech and is being commercialized by Indi Molecular.

Read More
Press ReleaseTori Cox